Sept 16 The U.S. Food and Drug Administration
said it approved Teva Pharmaceutical Industries Ltd's
generic version of Roche Holding AG's cancer drug
Teva Pharmaceuticals USA, a unit of the generic drugmaker,
will market 150 and 500 milligram doses of the oral drug, named
The drug, like Xeloda, will have a boxed warning about an
increased risk of bleeding in patients who are on blood thinners
Xeloda, which treats colorectal cancer and breast cancer
that spreads to other body parts, accounted for revenue of $1.52
billion swiss francs ($1.65 billion) last year, making it
Roche's fifth-largest drug.
The drug was to lose its patent protection at the end of
this year. Privately held Indian drugmaker Intas Pharmaceuticals
signed an agreement in June with Roche to sell generic Xeloda in
the United States before it lost exclusivity.